Summary by Moomoo AI
AbbVie announced that its Q3 2024 earnings will include an $82 million pre-tax expense for acquired IPR&D and milestones, impacting both GAAP and adjusted non-GAAP diluted EPS by $0.04. The company has revised its Q3 2024 adjusted diluted EPS guidance to $2.88-$2.92.Following this adjustment, AbbVie updated its full-year 2024 adjusted diluted EPS guidance range to $10.67-$10.87, incorporating the Q3 IPR&D expense impact. The total acquired IPR&D and milestone expenses for 2024 are now expected to reach $1.183 billion.The company noted that these results are preliminary and subject to financial statement closing procedures. Future IPR&D and milestone expenses beyond Q3 2024 are not included in the guidance due to uncertainty in timing and occurrence of such transactions.
